PBC Market Poised for Significant Growth to $X Billion by 2032 Driven by Rising Prevalence, Robust Pipeline
-
The primary biliary cholangitis (PBC) market size was $1.1 billion in 2022 in the 7 major markets (7MM) and is expected to grow significantly by 2032 due to rising prevalence, robust pipeline, and growing R&D.
-
There were about 291,000 diagnosed prevalent cases of PBC in the 7MM in 2022, with the highest number (139,000) in the US.
-
Key companies developing therapies for PBC include Ipsen, Zydus, Cour Pharma, Calliditas, CymaBay, Mirum, Intercept, Escient, and GlaxoSmithKline.
-
Pipeline therapies like elafibranor, saroglitazar magnesium, CNP-104, setanaxib, seladelpar, and others show potential in meeting unmet needs in PBC treatment.
-
Growth drivers for the PBC market include rising prevalence, robust pipeline, advancements in diagnosis, while growth barriers involve undiagnosed cases, treatment costs and burden, and discontinued emerging therapies.